Teva Pharmaceuticals Europe B.V. – Raising the bar in migraine prophylaxis
Exclusive symposium | Plenary hall | 12:45–01:45 p.m.
Welcome and introduction | Prof. Cristina Tassorelli |
CGRP pathway mAbs in Europe: 6 years of real-world practice, progress, and emerging perspectives | Prof. Cristina Tassorelli |
Optimising migraine prevention: Are we reaching the full potential of CGRP pathway-targeting therapies? | Assoc. Prof. Gregor Brössner |
CGRP ligand or receptor targeting: Does mechanism of action influence treatment response? | Dr. Francesca Puledda |
What’s next? How clinical experience is informing future directions | All |
Closing remarks and Q&A | All |
H. Lundbeck A/S – Real world evidence and the IHS position on treatment targets in migraine
Meet the expert | Booth no. 3 | 01:50-02:15 p.m.
| Speaker | Prof. Piero Barbanti |
AbbVie Inc. – Beyond headache days: Elevating migraine care through patient-centred dialogue
Headache Theatre | Industrial exhibition | 02:15–02:35 p.m.
| Speaker | Prof. Antoinette Maassen van den Brink |
| Speaker | Elena Ruiz de la Torre |
Pfizer Inc. – Acute treatment: Optimizing your patients’ acute treatment journey: harnessing real-world evidence on Rimegepant
Headache Theatre | Industrial exhibition | 03:20–03:40 p.m.
| Introduction | Prof. Antonio Russo |
| Who benefits from acute treatment with rimegepant? Aligning goals & guidelines with a patient-centred approach | Prof. Antonio Russo |
| Optimising acute migraine treatment with rimegepant: bridging guidelines, clinical trial data and real-world evidence | Prof. Antonio Russo |
| Q&A | Prof. Antonio Russo |
Organon Inc. – Neurologists and Gynaecologists working together: Improving lives of women with migraine
Exclusive symposium | Plenary hall | 03:45–04:45 p.m.
| Welcome and Introduction | Dr. William Kingston |
| What the neurologist needs to know about women´s reproductive years and beyond | Prof. Gabriele Merki |
| What the gynecologist needs to know about migraine | Prof. Gisela Terwindt |
| Multidisciplinary collaboration to improve lives of women with migraine | Faculty |
| Summary and Conclusion | Dr. William Kingston |
Dr. Reddy's Laboratories – Remote Electrical Neuromodulation: The next frontier in migraine management
Parallel Symposium | Breakout room 2| 09:30–10:30 a.m.
| REN in Migraine Care: Clinical Data at a Glance | Prof. Manjit Matharu |
| Understanding REN: How It Modulates Migraine Pain | Dr. David Yarnitsky |
| Case based Panel Discussion | Prof. Manjit Matharu |
Pfizer Inc. – Preventive treatment: Oral CGRP targeting therapies for first-line prevention of migraine: meeting patient needs with Rimegepant
Headache Theatre | Industrial exhibition | 10:35–10:55 a.m.
| Introduction | Dr. Peter McAllister |
| Unmet needs in prevention of episodic migraine | Dr. Peter McAllister |
| Exploring management in prevention of episodic migraine with rimegepant | Dr. Peter McAllister |
| Q&A | Dr. Peter McAllister |
AbbVie Inc. – Fight for Your Patients with Migraine: An Expert Exchange Challenging the Standard of Care in Acute and Preventive Treatment
Exclusive symposium | Plenary hall | 12:30–01:30 p.m.
Join our experts as they go head-to-head in two rounds of debate in this interactive symposium.
Our speakers will discuss exciting new data, review recommendations and challenge current and conventional paradigms in both the acute and preventive treatment of migraine.
WHO WILL WIN? YOU DECIDE.
| Round 1 A Focus on Acute: Is it Clinically Justified to Reserve Gepants for Patients Who Fail or Cannot Tolerate Triptans? | Ian Finkelstein (Chair) Håkan Ashina Annelies van Dycke |
| Round 2 A Focus on Prevention: What will be the Biggest Game-Changer to Standard of Care in the Preventive Management of Migraine? | Ian Finkelstein (Chair) |
v1.0 | Nov25 | AGPT-AA-00074-E
H. Lundbeck A/S – From Response to Decision: Defining When to Switch in Migraine Care
Meet the expert | Booth no. 3 | 01:35-02:00 p.m.
| Speaker | Prof. Jan Versijpt |
Teva Pharmaceuticals Europe B.V. – Integrating headache science and clinical practice for smarter migraine prevention
Headache Theatre | Industrial exhibition | 03:35–03:55 p.m.
| From lab to life: Bridging headache science and pharmacology | Dr. Anna Andreou |
| Applying headache science in daily practice | Dr. Giorgio Lambru |
Medtronic – Durability in Focus: L-ICON Multi-Year Results and the AnkerStim™ System for Medically Intractable Chronic Cluster Headache
Headache Theatre | Industrial exhibition | 05:00–05:20 p.m.
| Presentation of the L-ICON study, 8 years of long-term effectiveness of Occipital Nerve Stimulation (ONS) | Prof. Rolf Fronzcek |
| AnkerStim™ for treating intractable Chronic Cluster Headache (iCCH) | Prof. Rolf Fronzcek |
AbbVie Inc. – From data to decisions: Exploring TEMPLE data within the migraine preventive landscape
Headache Theatre | Industrial exhibition | 10.35–10.55 a.m.
| Speaker | PD Dr. Robert Fleischmann |
H. Lundbeck A/S – Timely treatment, optimised care: Solutions to shape migraine prevention
Exclusive symposium | Plenary hall | 11:00 a.m. –12:00 p.m.
| Why wait? Transforming outcomes for patients with migraine | Prof. Patricia Pozo-Rosich |
| To stay or to switch? Real-world migraine cases in action | Prof. Piero Barbanti |
| What is the future of migraine prevention? Neuropeptides in focus | Prof. Messoud Ashina |
AbbVie Inc. – Understanding the evolution of migraine care: From disease progression to tailoring treatment
Parallel Symposium | Breakout room 2| 01:30–02:30 p.m.
| Welcome & Introduction | Dr. Carlos Andrade |
| Our evolving understanding of migraine - what we thought then vs what we know now | Dr. Sian D. Spacey Dr. Carlos Andrade |
| Optimising patient management in the current treatment landscape | Dr. Carlos Andrade Dr. Sian D. Spacey |
| Breaking the burden: rethinking our understanding of migraine patients and providing personalised care | Dr. Carlos Andrade Dr. Sian D. Spacey |
| Summary and meeting close | Dr. Carlos Andrade |
Dr. Reddy's Laboratories – The Role of Remote Electrical Neuromodulation (REN) as a Dual Therapy in Migraine Management
Meet the expert | Booth no. 4 | 02:30-03:00 p.m.
| Speaker | Prof. Manjit Matharu |
H. Lundbeck A/S – VYEPTI®: Advancing migraine prevention through early intentional IV therapy
Headache Theatre | Industrial exhibition | 02:35–02.55 p.m.
Prof. Jan Versijpt will take an in-depth look at the clinical rationale behind VYEPTI®’s intentional IV design for migraine prevention. This session will explore how 100% bioavailability and rapid onset differentiate VYEPTI® from other anti-CGRP therapies. Real-world evidence and clinical trial data will be presented to examine the potential impact of earlier use of VYEPTI® in the treatment pathway on patient outcomes and disease course.
| Speaker | Prof. Jan Versijpt |
Pfizer Inc. – Tailoring the approach to migraine care along the treatment continuum
Exclusive symposium | Plenary hall | 03:00–04:00 p.m.
| Welcome and Introduction | Prof. Raquel Gil-Gouveia |
| Beyond triptans: Tailoring acute migraine treatment strategies to individual patient needs | Dr. Krishna Dani |
| Building CONFIDENCE in migraine management: Harnessing real-world evidence on consistency and patient satisfaction | Prof. Raquel Gil-Gouveia |
| Evolution from tradition to precision: Optimising preventive migraine care with CGRP-targeted strategies | Dr. Peter McAllister |
| Audience Q&A and Close | All |
Conventus Congressmanagement & Marketing GmbH
Roxelane Görls-Barry | Nadjana Sokol | Patrick Schreiber
Carl-Pulfrich-Strasse 1 • 07745 Jena, DE
ehc-industry@conventus.de
www.conventus.de